Merck & Co., Inc. is under intense scrutiny as insiders reportedly sell US$12m and later, US$15m of their shares, indirectly hinting at potential instability in the company. However, the pharmaceutical giant consistently outperformed competitors on numerous trading days. The flagship cancer drug Keytruda is making significant waves, leading to increased annual sales forecasts and garnering investor attention. Despite these gains, some believe Merck's stock is fully valued at $130. The company is also battling fluctuations in performance, with multiple instances of underperforming compared to competitors. Analysts believe that Merck presents a strong momentum and value stock for the long term, even as the company has had days where the stock sank. The FDA's approval of Merck's cardiovascular disease drug and the success of Keytruda have sparked debates on whether 2023 will be the year for the perceived laggard Merck to stage a comeback. Serious doubts persist, though, regarding the company's financial prospects despite the stock's uptrend. The most pivotal catalyst for Merck's stock in 2024 could be the launch of Sotatercept.
Merck Stocks News Analytics from Mon, 08 Jan 2024 08:00:00 GMT to Sun, 19 May 2024 01:39:34 GMT -
Rating 3
- Innovation -4
- Information 3
- Rumor -4
